Clinical Trial Update: PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study of PTC299 in pediatric patients with refractory or recurrent primary central nervous system tumors has completed. The trial assessed safety and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumors
• Central Nervous System Tumors

Drugs mentioned

• PTC299

Snippet

Sponsor: Pediatric Brain Tumor Consortium | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED